Cartherics grants Shunxi Licence for CAR-T Cell Therapy for Ovarian Cancer in Greater China
Melbourne, Australia, 28 April 2023 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has granted Shunxi Holding Group Co Ltd (“Shunxi”) a licence to develop, manufacture and commercialise Cartherics’ autologous CAR-T cell product, CTH-004, for the treatment of multiple solid tumours including […]
